1. Introduction {#sec1-cancers-12-01020}
===============

Ovarian cancer (OC) is the second most common cause of death worldwide due to gynecological cancers. There were some 295,000 new cases and 185,000 deaths around the globe in 2018, with increasing trends predicted \[[@B1-cancers-12-01020]\]. According to the type of cell in which the tumor originates, OC can be classified as stromal, germinal or epithelial (EOC), the latter being the most common, accounting for 90% of cases. Within EOC, five histological subtypes can be distinguished: high-grade serous, low-grade serous, mucinous, clear-cell and endometrioid. They are distinguished on the basis of histological structure; mutations in certain proto-oncogenes or tumor suppressor genes; chemosensitivity; spreading behavior; and the most worrisome, prognosis. Little is known about the etiology of the disease, although some genetic and environmental risk factors have been identified; e.g., BRCA1/2 mutations, and low or null parity, respectively. OC, and EOC patients particularly, are usually diagnosed at an advanced stage of the disease owing to the asymptomatic character of the tumor during its onset and initial development, leading to a five-year overall survival rate below 40% \[[@B2-cancers-12-01020]\]. In contrast, early diagnosis correlates with a much better prognosis. Unfortunately, no early biomarkers have been approved for clinical use so far, although some attempts have been made using multivariate index assays, such as the risk of ovarian malignancy algorithm (ROMA) or Overa \[[@B3-cancers-12-01020]\]. The first-line treatment of OC consists of surgical resection of the tumor and administration of platinum derivatives, taxanes and/or bevacizumab, which is a monoclonal antibody targeting vascular endothelial cell growth factor (VEGF). Additionally, olaparib, which is an inhibitor of poly (ADP-ribose) polymerase (PARPi), was authorized as first-line maintenance treatment for BRCA-mutated high-grade serous OC patients who have shown complete or partial response to platinum. Despite the benefits of these therapies, most patients experience relapses and the tumor even becomes resistant to the treatment. As a second-line treatment, PARPi, doxorubicin or gemcitabine are administered \[[@B4-cancers-12-01020]\].

Long non-coding RNAs (lncRNAs) are transcripts that were identified in genomic studies during the late 1990s and 2000s. They are defined as longer than 200 nucleotides and are presumed not to encode proteins. The peculiarity of lncRNAs is their ability to regulate gene expression at many different levels, by modulating chromatin remodeling, transcription, and alternative splicing, and generating micro RNAs (miRNAs) or producing short biologically active peptides \[[@B5-cancers-12-01020]\]. They actively participate in all the events involved in tumor development and spread, and even in treatment resistance in bladder cancer, colorectal cancer, multiple myeloma and others, including OC \[[@B6-cancers-12-01020]\]. Additionally, their expression is tissue-specific \[[@B7-cancers-12-01020]\] and they can be detected in fluids, making them potential biomarkers \[[@B8-cancers-12-01020]\]. LncRNAs have not been as deeply studied as their counterparts, miRNAs, and many questions remain about their mechanisms of action and effects in the context of cancer, including OC. Interestingly, the number of different lncRNAs associated with OC, and consequently publications on the topic, has recently grown exponentially ([Figure 1](#cancers-12-01020-f001){ref-type="fig"}), making previous reviews out-of-date owing to the overwhelming mass of data being produced. The aim of this review is to update and compile information about the lncRNAs related to OC; their importance in the clinical setting as diagnostic and prognostic tools; and their relationship to cancer hallmarks and their molecular mechanisms of action in the cell. In addition, we briefly comment on the online bioinformatics tools used in the reviewed papers. Finally, future work required in the field is also discussed along with some concluding remarks.

2. Clinical Relevance of LncRNA in OC: Diagnosis, Prognosis and Treatment Resistance {#sec2-cancers-12-01020}
====================================================================================

As mentioned above, there are currently no efficient and routine methods for early diagnosis of OC. Only in a minority of cases, wherein the condition is suspected on the basis of either unspecific symptoms or familial antecedents, can preventive measures be taken, such as gynecological explorations; imaging techniques, such as transvaginal sonography; or blood tests to measure cancer antigen 125 (CA-125) together with other proteins with informative value, such as transferrin or HE4 \[[@B3-cancers-12-01020]\]. If a tumor is detected, further and more sophisticated explorations are conducted: imaging techniques such as computed tomography (CT) or positron emission tomography (PET), and laparotomy or surgery to: (i) extract a sample for biopsy/histology-based diagnosis, (ii) study the extent of the disease (localized or generalized-staging) and/or (iii) proceed with therapeutic surgical debulking/cytoreductive surgery of the tumor \[[@B4-cancers-12-01020]\]. These techniques are either nonspecific or only valid for late detection \[[@B3-cancers-12-01020]\].

In the process of developing new, specific, differential molecular markers for OC, lncRNAs are proposed as a new generation of clinical tools. They have been studied in OC patient samples using reverse transcription quantitative polymerase chain reaction (RTqPCR), microarray hybridization and (fluorescence) in situ hybridization ((F)ISH), mainly from cancerous tissue, and compared with adjacent normal tissue or samples from healthy patients. Usually, their levels differ from those in the controls ([Table S1](#app1-cancers-12-01020){ref-type="app"}), and such aberrant lncRNA expression also correlates with clinicopathological parameters, such as histological type, tumor size or metastasis ([Table 1](#cancers-12-01020-t001){ref-type="table"}).

The presence of several lncRNAs has been correlated with epithelial subtypes. For instance, Casc2 and FLJ33360, respectively, distinguish the serous and high-grade serous subtypes from the others \[[@B17-cancers-12-01020],[@B66-cancers-12-01020]\]; SNHG15 differentiates low-grade serous, mucinous, endometrioid and clear cell from high-grade serous, endometrioid and non-differentiated \[[@B67-cancers-12-01020]\]. The expression of many lncRNAs associated with OC, namely, ANRIL, CCAT1, CCAT2, EIBC, GAS5, HOXA11-AS, lncARSR, lncBRM, Lnc-OC1, MIR4697HG, NEAT1, SOX2OT \[[@B6-cancers-12-01020]\] and SOCAR \[[@B64-cancers-12-01020]\], also correlate with blood levels of CA-125, which could improve the patient's follow-up, since lncRNAs are highly cancer-specific \[[@B7-cancers-12-01020]\].

The spreading of OC in patients is classified into four stages according to the International Federation of Gynecology and Obstetrics (FIGO), which in addition to tumor size and histological grade/cell-dedifferentiation correlates negatively with the prognosis and survival of patients \[[@B68-cancers-12-01020]\]. LncRNA expression correlates with FIGO staging ([Table S1](#app1-cancers-12-01020){ref-type="app"}), either grouping I--II and III--IV as in ABHD11-AS1 \[[@B10-cancers-12-01020]\], or discerning each of the four stages precisely, as reported for AGAP2-AS1 \[[@B69-cancers-12-01020]\]. In this review, we will focus on the clinicopathological variables associated specifically with each of the FIGO stages. FIGO stage I means the tumor is limited to the ovaries; the main studied variable that affects this stage is primary tumor size. The bigger the tumor, the more developed it is and the poorer the prognosis, although this criterion could be misleading because some tumors are benign. The histological grade, that is, the state of tumor cell dedifferentiation, relates to the tendency of the tumor to invade surrounding tissues and organs. It is associated with FIGO stage II and with the malignancy and aggressiveness of the tumor. The next phase of tumor progression is the acquisition of invasive capacity, which finally determines how close the tumor can get to adjacent tissues or vessels. Both GAS5 \[[@B22-cancers-12-01020]\] and MLK7-AS1 \[[@B40-cancers-12-01020]\] correlate with the depth of tumor invasion. Once the tumor cells reach vessels, they usually invade lymph nodes first (FIGO stage III) and the peritoneal cavity because of its proximity, but eventually other organs are reached (FIGO stage IV). Correlations between FIGO stages and the associated clinicopathological features are not always perfect, perhaps because of experimental variability.

Besides their diagnostic value, individual lncRNAs can predict the survival of OC patients according to their levels in the cohorts studied, yielding different survival outcomes between patients with high and low lncRNA expression levels. As seen in [Table 2](#cancers-12-01020-t002){ref-type="table"}, most of them correlate with patients' overall survival (OS), whereas fewer correlate with progression-free survival (PFS) or disease-free survival (DFS) periods, as shown in [Table 3](#cancers-12-01020-t003){ref-type="table"}.

LncRNAs are clinically important in the context of OC in another sense because they are known to be active in developing resistance to treatments ([Table 4](#cancers-12-01020-t004){ref-type="table"}), leading to relapse and poor patient prognosis. Most of these have been associated with resistance to chemotherapeutics. The most widespread clinical treatments are platinum salts such as cisplatin or carboplatin, and taxanes such as paclitaxel \[[@B4-cancers-12-01020]\]. Depending on their specific roles, lncRNAs can either promote or reduce resistance to the treatment, as summarized in [Table 4](#cancers-12-01020-t004){ref-type="table"}.

Some have been implicated in resistance to experimental drugs such as bufalin and physcion 8-O-B-glucopyranoside; for example, NORAD \[[@B115-cancers-12-01020],[@B116-cancers-12-01020]\]. Some, such as CTD-2589M5.4, which is co-expressed with some ATP-binding cassette (ABC) genes, are only indirectly related to chemoresistance \[[@B102-cancers-12-01020]\]. One, FAM83H-AS, has even been identified as conferring radioresistance in vitro \[[@B15-cancers-12-01020]\].

LncRNAs can also help to stratify patients for treatment choice in order to increase responsiveness and efficacy. This is the case for SNHG5 in reference to paclitaxel \[[@B62-cancers-12-01020]\], and for RP11-135L22.1 \[[@B48-cancers-12-01020]\] and LINC00515 \[[@B56-cancers-12-01020]\] regarding platinum drugs. The expression of these lncRNAs differs between responder and non-responder patients, which enables their stratification. NEAT1 is the only lncRNA identified so far as being involved in resistance to olaparib (PARPi) treatment, which is a targeted therapy against BRCA1/2-mutated tumors \[[@B105-cancers-12-01020]\].

Despite great efforts to use these advances in the clinic, only six of the lncRNAs listed in [Table S1](#app1-cancers-12-01020){ref-type="app"} have been identified in OC patients' blood serum samples; namely, E2F4AS \[[@B117-cancers-12-01020]\], FEZF1-AS1 \[[@B20-cancers-12-01020]\], FLVCR1-AS1 \[[@B41-cancers-12-01020]\], LINK-A \[[@B26-cancers-12-01020]\], MLK7-AS1 \[[@B40-cancers-12-01020]\] and aHIF \[[@B13-cancers-12-01020]\], the last-named being isolated specifically from exosomes in the serum. MEG3 and MALAT1 are probably on the way to being added to the list since they have been identified in exosomes derived from OC cell lines \[[@B26-cancers-12-01020],[@B107-cancers-12-01020]\]. Interestingly, the serum and tumor tissue levels of aHIF, FEZF1-AS1, FLVCR1-AS1, LINK-A, and MLK7-AS1 correlate positively, providing a proof of concept for the usefulness of lncRNAs in liquid biopsy. Such is the interest caused by these findings that there are currently two ongoing clinical trials on lncRNAs for OC, one aiming to search lncRNAs in exosomes from patients \[[@B118-cancers-12-01020]\], and the other to discover new lncRNAs implicated in OC by a multi-omic approach \[[@B119-cancers-12-01020]\].

3. LncRNAs Implicated in OC Development and Progression {#sec3-cancers-12-01020}
=======================================================

The study of lncRNAs is an emerging field. According to GENCODE Release 33 \[[@B120-cancers-12-01020]\], the number of lncRNA genes known at the time of submission of this review was 17,952 (16,892 already confirmed and 1060 to be experimentally confirmed). Only a small portion has been studied in detail; and of these, to the best of our knowledge, just 215 have been proven to be involved in OC so far ([Table S1](#app1-cancers-12-01020){ref-type="app"}).

Long non-coding RNAs, as key regulators of gene expression at different levels, take part in many physiological processes. Their dysregulation can, therefore, contribute to the aberrant functioning of the cell leading to different diseases, including cancer \[[@B6-cancers-12-01020],[@B121-cancers-12-01020]\].

Although a few of them are best known/studied in the OC context, e.g., MALAT1, HOTAIR, H19, XIST, UCA1, PVT1, GAS5 and MEG3, 157 different lncRNAs have been shown experimentally to be associated with OC ([Table S1](#app1-cancers-12-01020){ref-type="app"}). Of these, around 50%, 81, have not been cited in previous reviews but participate actively in OC. Most experiments so far reported are based on the knockdown or overexpression of specific lncRNAs in different cancer cell lines and assessments of their corresponding cancer-related phenotypes in culture (in vitro) or with xenografts (in vivo) ([Figure 2](#cancers-12-01020-f002){ref-type="fig"}a). Surveying the function of lncRNAs globally ([Figure 2](#cancers-12-01020-f002){ref-type="fig"}b), 120 are considered as oncogenes, 114 confirmed and six putative; and 29 are considered as tumor suppressor genes, 25 confirmed and four putative. SPRY-IT1 \[[@B26-cancers-12-01020]\], MEG3 \[[@B122-cancers-12-01020],[@B123-cancers-12-01020]\], XIST \[[@B54-cancers-12-01020],[@B99-cancers-12-01020]\] and TTN-AS1 \[[@B65-cancers-12-01020],[@B124-cancers-12-01020]\] statuses remain unclear because the shreds of evidence collected are ambiguous. The experimental data about TC0101686, TC0100223, TC0901107, and TC1500845 show only that they are transcriptionally activated by estrogens. No phenotypic consequence of dysregulation of these latter four lncRNAs has been reported \[[@B42-cancers-12-01020]\].

LncRNAs are involved in proliferation, tumor growth in vivo, cell cycle control, cell death, migration, invasion, epithelial-to-mesenchymal transition (EMT), metastasis in vivo, angiogenesis and cell metabolism, all related to the hallmarks of cancer \[[@B125-cancers-12-01020]\]. The only two hallmarks of cancer that have not yet been related to lncRNA in the context of OC are "genomic stability and mutation" and "enabling replicative immortality."

The most studied characteristic, and also the most frequently affected by changes in lncRNA expression, accounting up to 119 different lncRNAs, is anchorage-dependent cell proliferation, which determines cell division rate and viability. Closely related to this, and affected by fewer lncRNAs, is anchorage-independent cell proliferation, which measures the ability of cells to survive and proliferate in the absence of a solid support, a characteristic of malignant cells. After mouse xenografting, lncRNAs have also been shown to influence the size and weight of the tumor, some replicating the same scenario as in patients, such as AB073614 \[[@B9-cancers-12-01020]\], EPB41L4A-AS2 \[[@B23-cancers-12-01020]\], GAS5 \[[@B22-cancers-12-01020]\], KCNQ1OT1 \[[@B35-cancers-12-01020]\], LINC00565 \[[@B37-cancers-12-01020]\], TINCR \[[@B51-cancers-12-01020]\] and TPT1-AS1 \[[@B53-cancers-12-01020]\].

Loss of cell cycle control is also a consequence of lncRNA dysregulation, as in the case for MNX1-AS1 \[[@B6-cancers-12-01020]\] and SPRY4-IT1 \[[@B26-cancers-12-01020]\], described previously; and KB-1471A8.2 \[[@B103-cancers-12-01020]\] and Casc15 \[[@B12-cancers-12-01020]\], which were recently shown to be relevant in this context. This effect is exerted by ultimately controlling the expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinases inhibitors, influencing G~0~ arrest or cell cycle halting. These features are related to the cancer hallmarks of proliferative signal maintenance and evasion of growth suppressors, described by Hanahan and Weinberg.

Avoidance of cell death, causing cell immortalization, is another important hallmark of cancer. The most studied type of cell death is apoptosis, regulated by lncRNAs such as HAL \[[@B126-cancers-12-01020]\] and LncRNA-ATB \[[@B127-cancers-12-01020]\] among others. However, GAS5 can trigger the formation of the inflammasome, leading to pyroptosis, a highly inflammatory type of programmed cell death \[[@B128-cancers-12-01020]\]. In this regard, some lncRNAs have been proven to induce the autophagic response, as with MEG3 \[[@B6-cancers-12-01020]\] and MALAT1 \[[@B107-cancers-12-01020]\], or inhibit it, as with HOTAIR \[[@B26-cancers-12-01020]\], HULC \[[@B6-cancers-12-01020]\] and RP11-135L22.1 \[[@B48-cancers-12-01020]\]. Importantly, these groupings do not coincide with oncogene or tumor suppressor status; the net effect of autophagy in the context of cancer has been questioned because its outcomes are ambiguous \[[@B129-cancers-12-01020]\].

Migration and invasion in vitro are, after AD proliferation, the characteristics most commonly influenced by lncRNAs, representing motility and the ability to degrade the extracellular matrix. Many of the lncRNAs described in OC ([Table S1](#app1-cancers-12-01020){ref-type="app"}) can affect the EMT process, as demonstrated through molecular markers such as Snail, Slug, E-cadherin, N-cadherin, and Vimentin \[[@B130-cancers-12-01020]\]. Finally, in vivo metastasis is also influenced by lncRNAs, some of which recapitulate patients' fate and/or tumor behavior, as in the case of DANCR \[[@B11-cancers-12-01020],[@B131-cancers-12-01020]\], FAM83H-AS1 \[[@B15-cancers-12-01020]\], MAGI1-IT1 \[[@B34-cancers-12-01020]\], MLK7-AS1 \[[@B40-cancers-12-01020]\] and TPT1-AS1 \[[@B53-cancers-12-01020]\]. These four features (migration, invasion, EMT and in vivo metastasis) are associated with the hallmark "invasion and metastasis."

Interestingly, although this effect has been less studied, some lncRNAs control cell metabolism by regulating key enzymes in metabolic pathways, contributing mainly to stimulating glycolysis instead of aerobic metabolism (the Warburg effect). In the glycolysis pathway from glucose to pyruvate, the expression of hexokinase 2, catalyzing the first step, is activated by LINC00504 \[[@B70-cancers-12-01020]\]; NRCP activates the second enzyme in the pathway, glucose-6-phosphate isomerase \[[@B26-cancers-12-01020]\]; after that, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 is induced by LINC00092 \[[@B31-cancers-12-01020]\]; in the fourth step catalyzed by aldolase, two forms of the enzyme, A and C, are activated by NRCP \[[@B26-cancers-12-01020]\]. The final step is catalyzed by pyruvate kinase isozyme M2, which is activated by both LINC00504 and H19 \[[@B70-cancers-12-01020],[@B132-cancers-12-01020]\]. Moreover, LINC00504 activates the expression of pyruvate dehydrogenase kinase 1 (PDK1), which inhibits pyruvate dehydrogenase by phosphorylation \[[@B70-cancers-12-01020]\], thereby inhibiting the Krebs cycle. SNHG3 is known to affect metabolism but its net effect on metabolic switching is not clear since it activates key enzymes in glycolysis such as pyruvate kinase, but also Krebs cycle enzymes such as pyruvate dehydrogenase and isocitrate dehydrogenase, and oxidative phosphorylation components, such as ubiquinol--cytochrome c reductase hinge protein \[[@B88-cancers-12-01020]\]. Less directly, GHET1 \[[@B24-cancers-12-01020]\] and LINK-A \[[@B26-cancers-12-01020]\] are also related to metabolic switching, since they regulate the expression of HIF1a, which is also responsible for inducing the Warburg effect.

Angiogenesis is a driving force for tumors owing to increased vascularization, which guarantees nutrient delivery for tumor growth and provides a route through which malignant cells can colonize other tissues. Although angiogenesis is a hallmark of cancer and an important therapeutic target, only a few published studies have addressed the role of lncRNAs in it. It has been established that MALAT1 promotes angiogenesis by inducing VEGF and fibroblast growth factor expression in OC \[[@B105-cancers-12-01020]\], but recently two others have also been shown to have pro-angiogenic properties, named DANCR \[[@B133-cancers-12-01020]\] and HNF1A-AS1 \[[@B134-cancers-12-01020]\]. They activate the expression of VEGF and SEMA4D, respectively, which are powerful inducers of blood vessel formation. Since HIF1a, which is regulated by GHET1 and LINK-A, controls VEGF expression, these two lncRNAs are also related to angiogenesis.

A few lncRNAs, such as AC104699.1.1 and RP11-284N8.3.1, which are related to activation of the tumor microenvironment, are also involved in promoting inflammation \[[@B26-cancers-12-01020]\]. Interestingly, GAS5 can activate pyroptosis, which, as mentioned in the cell death paragraph, triggers an excessive inflammatory response, collaborating with tumor progression \[[@B128-cancers-12-01020]\].

Only one lncRNA, HOTTIP, has been cited in reference to the avoidance of immune surveillance. Others, such as CTD-20202K17.1, are indirectly related to this cancer hallmark. HOTTIP increases the expression and secretion of IL-6 by tumor cells, which triggers PD-L1 expression through the STAT3 pathway in neutrophils \[[@B87-cancers-12-01020]\]. CTD-2020K17.1 controls CARD11 expression, which is proposed to modulate tumor immune-surveillance \[[@B135-cancers-12-01020]\].

4. Regulatory Molecular Mechanisms of LncRNAs in OC {#sec4-cancers-12-01020}
===================================================

The phenotypes described are a consequence of target gene regulation by lncRNAs by different mechanisms, affecting gene expression at the transcriptional, post-transcriptional and post-translational levels in OC ([Figure 3](#cancers-12-01020-f003){ref-type="fig"}).

4.1. Transcriptional Regulation {#sec4dot1-cancers-12-01020}
-------------------------------

LncRNAs can regulate transcription in two different ways according to their locations of action in relation to their own transcription sites. Their effects can be exerted either at the same or a nearby locus, i.e., in cis, or at distant sites on the same or different chromosomes, i.e., in trans.

LncRNAs can associate with transcriptional protein complexes to modulate their function, changing their capacity to bind DNA and modulate the transcription of target genes via signaling, guide, decoy and/or scaffold mechanisms. By the signaling mechanism, lncRNAs participate in transcriptional machinery or transcription factor (TF) recruitment to the promoter of their downstream-regulated genes. They either promote transcription by facilitating RNA polymerase binding, as in the case of HOTTIP, which binds to c-Jun to promote IL-6 transcription \[[@B87-cancers-12-01020]\]; or, in contrast, repress transcription, as in the case of GAS5, which brings E2F4 to the PARP1 promoter region, precluding RNA polymerase binding \[[@B46-cancers-12-01020]\].

In another described mechanism, lncRNAs guide specific epigenetic repressors such as polycomb repressive complexes (PRC) to the locus of a certain gene by a mechanism based on DNA-RNA complementarity, leading to histone modification and therefore to gene silencing. This kind of regulation can be also in cis, although no examples have yet been described for OC. However, several examples have been described in OC for lncRNA-based PRC2 guidance, specifically of EZH2, an active subunit of PRC, to the loci of target genes: LINC00511 and TP73-AS1 guide EZH2 to the p21 locus \[[@B72-cancers-12-01020],[@B95-cancers-12-01020]\]; LINC00702 guides it to the KLF2 locus \[[@B39-cancers-12-01020]\]; LINC01210 to the KLF4 locus \[[@B27-cancers-12-01020]\]; ABHD11-AS1 to the TIMP2 locus \[[@B136-cancers-12-01020]\]; and UNC5B-AS1 to the NDRG2 locus \[[@B137-cancers-12-01020]\].

LncRNAs can also act as decoys to sequester TFs, disabling their interaction with their target gene promoters, like "protein sponges"; i.e., decreasing their affinity with DNA. GAS5 acts as a decoy with the activator CEBPB, precluding its interaction with the GDF15 promoter, thereby inhibiting its transcription \[[@B138-cancers-12-01020]\]. Similarly, GHET1 prevents the binding of VHL to the HIF-1 promoter \[[@B24-cancers-12-01020]\].

LncRNAs can also act as a scaffold by interacting with two or more proteins simultaneously, bringing them together and stabilizing the complex formed. For instance, lncRNA NRCP joins STAT1, which is a TF implicated in the JAK/STAT signaling pathway, and RNA Pol II \[[@B26-cancers-12-01020]\].

These categories are not mutually exclusive. For instance, Linc00176 acts as a scaffold to keep BCL3 and p50 together (NF-κB family) and at the same time recruits this complex to the ceruloplasmin promoter to activate its expression \[[@B139-cancers-12-01020]\]. Some reports of transcriptional regulation by lncRNAs do not fit this classification at all, as in the case of FAL1, which increases the stability of BMI (another subunit of PRC), thereby allowing epigenetic marking of the p21 gene to be silenced \[[@B31-cancers-12-01020],[@B42-cancers-12-01020]\].

Apart from trans regulation, lncRNAs can affect the transcription of neighboring genes. They usually regulate in cis the transcription of a sense gene that normally encodes a protein; this is the case for As-SLC7A11, which negatively regulates SLC7A11 \[[@B6-cancers-12-01020]\], or BACE1-AS and TPT1-AS1, which positively regulate BACE1 \[[@B21-cancers-12-01020]\] and TPT1 \[[@B53-cancers-12-01020]\]. They can also transcriptionally regulate nearby genes, as in the case of ANRIL, the expression of which correlates positively with the master tumor suppressors p14-ARF and p15-CDKN2B in normal tissues, and much more positively and statistically significantly with p14-ARF, p16-CDKN2A and p15-CDKN2B in tumor tissues \[[@B140-cancers-12-01020]\]. Indirect evidence shows that the lncRNAs ADAMTS9-AS1, RP11-597D13.9, FAS-AS1, AC093818.1, AK130076, GTSE1-AS1, and RP11-199F11.2 could be associated with ADAMTS9, FAM138B, FAS, PDK1, PTEN, GTSE1, and TP53 coding genes, respectively, all of them being implicated in OC \[[@B14-cancers-12-01020],[@B42-cancers-12-01020]\].

4.2. Post-Transcriptional Regulation {#sec4dot2-cancers-12-01020}
------------------------------------

The most frequently identified regulatory mechanism of action of lncRNAs is acting as competing endogenous RNAs (ceRNA) with miRNAs, which regulate the fate of mRNAs that encode proteins involved in cancer. These regulatory relationships among ncRNAs are not mutually exclusive, and several lncRNAs can act on the same miRNA targets, such as ANRIL, H19, and HOST2 that sequester let-7a, which regulates the expression of HMGA2, c-Myc, IGF2BP, Dicer and IMP3; and HOTAIR, lncARSR, and MALAT1 that sequester miR-200c, which modulates the expression of EMT regulators such as ZEB1/2 or Snail. [Table 5](#cancers-12-01020-t005){ref-type="table"} presents the numerous lncRNA/miRNA/mRNA axes so far known to be involved in OC. Another mode of post-transcriptional regulation is the sequestering of RNA processing factors. LncRNA Casc2 sequesters (decoys) EIF4A3, which takes part in splicing and is associated with monitoring mRNA quality before translation is initiated, thereby preventing the translation of proteins involved in the NF-κB, PI3K, and AKT signaling pathways \[[@B141-cancers-12-01020]\].

4.3. Post-Translational Regulation {#sec4dot3-cancers-12-01020}
----------------------------------

According to bioinformatics predictions, SNHG3 could interact with EIF4IIIA, a factor involved in regulating protein translation \[[@B88-cancers-12-01020]\]. Otherwise, no lncRNAs have been described as significant in regulating protein translation in the context of OC. However, they can have important post-translational effects by modulating the half-lives of the proteins they bind by stabilizing them, as in the case of ABHD11-AS1 and RhoC \[[@B10-cancers-12-01020]\]; DANCR and UPF1 \[[@B11-cancers-12-01020]\]; and FAM83H-AS1 and HuR \[[@B15-cancers-12-01020]\]. UCA1 can act as a scaffold between two proteins; e.g., for cytoplasmic Yes-associated protein (YAP) and angiomotin, it promotes YAP dephosphorylation and its translocation to the nucleus to act as a transcription coactivator \[[@B157-cancers-12-01020]\]. Other examples of post-translational regulation are the lncRNA HAL, which interacts with Twist1, this interaction being important for promoting EMT \[[@B126-cancers-12-01020]\], and the lncRNA HULC, which interacts with ATG7 and inhibits the autophagy pathway \[[@B6-cancers-12-01020]\].

We can find examples in which one lncRNA belongs to more than one of these categories according to its molecular mechanisms of action. For instance, the lncRNA NEAT1 can bind/sequester at least four different miRNAs: miR-194, miR-382-3p, miR-506 and miR-124-3p \[[@B6-cancers-12-01020],[@B21-cancers-12-01020],[@B105-cancers-12-01020]\]. Another example is the lncRNA miR503HG, which regulates miR-31-5p, surprisingly at both the transcriptional level by promoting the methylation of its promoter region, and post-transcriptionally by sequestering it, thereby preventing its union with the target mRNAs \[[@B100-cancers-12-01020]\]. Similarly, PVT1 guides EZH2 to the miR-214 promoter and simultaneously sequesters miR-133a \[[@B26-cancers-12-01020]\] and miR-140 \[[@B74-cancers-12-01020]\]. NCK1-AS1 binds to c-Cbl to protect it from ubiquitination, thereby precluding proteasomal degradation, and it also regulates its own sense transcript by sequestering miR-137, which binds to NCK1 mRNA \[[@B114-cancers-12-01020]\].

4.4. Regulation of LncRNA Expression {#sec4dot4-cancers-12-01020}
------------------------------------

Due to their ability to modulate the behavior of OC cells, the regulation of lncRNAs in itself is a matter for study, and some research has been done on this topic.

Some physiological conditions can trigger the transcription of certain lncRNAs, such as aHIF \[[@B158-cancers-12-01020]\], which is induced under hypoxic conditions like those existing in the tumor microenvironment. Several lncRNAs are modulated by, e.g., estrogens in the case of TC0100223, TC0101441, TC0101686, TC0901107 and TC1500845 \[[@B42-cancers-12-01020]\]; and also by some experimental drugs, as Casc2 is promoted by sanguinarine; anisomycin activates BACE1-AS \[[@B21-cancers-12-01020]\] and MEG3 \[[@B123-cancers-12-01020]\]; sinomenine hydrochloride inhibits HOST2 \[[@B83-cancers-12-01020]\]; actinomycin D promotes MEG3 transcription \[[@B42-cancers-12-01020]\]; or valproic acid inhibits H19 \[[@B107-cancers-12-01020]\]. For lncRNAs considered as tumor suppressor genes, hypermethylation of the coding gene promoter can cause downregulation, and hence OC, as with ZNF300P1, which was found to be hypermethylated in about 80% of OC cases \[[@B42-cancers-12-01020]\]. Demethylating agents such as 5'-AZA-2' or curcumin effectively restore the expression of lncRNAs such as MEG3 \[[@B26-cancers-12-01020]\] or MAGI2-AS3 \[[@B149-cancers-12-01020]\].

There are examples in which the TFs responsible for lncRNA transcription have been detected. Thus, CREB1 activates HAS-AS2 transcription \[[@B79-cancers-12-01020]\]; FOXO4 activates PVT1 transcription \[[@B74-cancers-12-01020]\]; Nkx3-1, HNF-1, aMEF-2 and MEF-2A are TFs take part in the transcriptional regulation of LOC100190986 \[[@B21-cancers-12-01020]\]. Some signaling pathways that trigger lncRNA transcription have also been identified; for instance, CXCL14 produced by surrounding fibroblasts triggers LINC00092 transcription \[[@B31-cancers-12-01020]\]; TGF-β1 activates MALAT1 \[[@B21-cancers-12-01020]\], PTAR \[[@B154-cancers-12-01020]\] and PTAL \[[@B153-cancers-12-01020]\] transcription; or pEGFR activates ABHD11-AS1 through STAT3 \[[@B136-cancers-12-01020]\]. The lncRNA UCA1 has been described as being activated by a super-enhancer \[[@B157-cancers-12-01020]\].

The regulatory network becomes more complicated when lncRNAs regulate each other, as in the cases of MEG3 regulated by AGAP2-AS1 \[[@B69-cancers-12-01020]\]; NEAT1 regulated by LSINCT5 \[[@B21-cancers-12-01020]\]; or the tight relationship between Lnc-SOX4-1 and PVT1 \[[@B42-cancers-12-01020]\]. A regulatory feedback loop has been discovered between Casc15 and miR-221 \[[@B12-cancers-12-01020]\]. Finally, lncRNAs can be stabilized by post-transcriptional modifications, such as RHPN1-AS1 methylation \[[@B77-cancers-12-01020]\], or by proteins, such as HuR, which binds NEAT1 \[[@B6-cancers-12-01020]\], at the extent of OC.

5. Bioinformatics Resources for LncRNA Research {#sec5-cancers-12-01020}
===============================================

The aim in this final section is to review the online tools available for lncRNA research and used in many of the articles compiled in this review in reference to OC. These web-based resources consist of the databases shown in [Table 6](#cancers-12-01020-t006){ref-type="table"}, which allow researchers to gain access to a vast amount of information in an easy and localized way, and/or the prediction tools shown in [Table 7](#cancers-12-01020-t007){ref-type="table"}, which are mostly user-friendly, avoid the constraints of bioinformatics programming and do not require expert or advanced knowledge.

One of the most used databases is GEPIA \[[@B159-cancers-12-01020]\], which offers customizable analysis of expression levels in tumors and normal samples using the RNA-sequencing data obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression Portal, respectively. Similarly, Cancer Cell Line Encyclopedia (CCLE) \[[@B160-cancers-12-01020]\] collects information, including details of lncRNAs, about gene expression, mutations and methylation status in more than a thousand cancer cell lines. TANRIC \[[@B161-cancers-12-01020]\] combines information from TCGA, CCLE and independent datasets, focusing on lncRNA expression profiles in an interactive display.

Since the study of lncRNAs is an emerging but growing field, and some lncRNAs can be functionally identified as new transcripts, a consensus for indexing the different aliases needs to be established, a mission covered by several databases, such as LNCipedia \[[@B162-cancers-12-01020]\], NONCODE \[[@B163-cancers-12-01020]\], AnnoLnc \[[@B164-cancers-12-01020]\], lncRNAdb \[[@B165-cancers-12-01020]\] or lncRBase \[[@B166-cancers-12-01020]\], containing annotations and gene information.

There are also databases that record the already-described interactions between lncRNAs and DNA, other RNAs and proteins in different contexts, enabling new mechanisms of action to be discovered. For instance, RNAInter \[[@B167-cancers-12-01020]\] and StarBase-ENCORI \[[@B168-cancers-12-01020]\] contain a vast, multi-omic-based amount of information about whole RNA interactomes, whereas miRTarBase \[[@B169-cancers-12-01020]\] is only valid for miRNA interactions. In other databases, information about how lncRNAs are regulated can be retrieved, as in the case of ORTI \[[@B170-cancers-12-01020]\], which contains information relating to TFs and their regulated genes, including lncRNAs. One reason why gene expression can be dysregulated is methylation status. This can be looked up easily in DiseaseMeth \[[@B171-cancers-12-01020]\], which collects aberrant human methylomes; or more specifically for this topic, in Lnc2Meth \[[@B172-cancers-12-01020]\], which includes regulatory relationships between human long non-coding RNAs and DNA methylation.

Two databases have mainly experimental purposes; namely, LncRNA2Target \[[@B173-cancers-12-01020]\] and CRISPRlnc \[[@B174-cancers-12-01020]\]. The former collects lncRNA knockdown or overexpression experiments in human and mouse to check target genes by immunoprecipitation, RNA pull-down, immunofluorescence, microarray hybridization or RNA-seq techniques. The latter contains a curated database with experimental evidence of single guide RNAs to perform knockouts of lncRNAs in different species.

Finally, there are several databases for specific relationships between lncRNAs and diseases, such as LncTarD \[[@B176-cancers-12-01020]\] and LncRNA disease \[[@B177-cancers-12-01020]\]; or, more specifically in the context of cancer, LncMAP \[[@B178-cancers-12-01020]\], Lnc2Cancer \[[@B179-cancers-12-01020]\], CRlncRNA \[[@B180-cancers-12-01020]\], EMT-Regulome \[[@B181-cancers-12-01020]\] and RHPCG \[[@B182-cancers-12-01020]\].

Apart from databases, there are useful tools for predicting the behavior of lncRNAs in terms of molecular interactions. Some of these can predict interactions with proteins, such as RPISeq \[[@B183-cancers-12-01020]\], RPI-Pred \[[@B184-cancers-12-01020]\], lncPro \[[@B185-cancers-12-01020]\] and catRAPID \[[@B186-cancers-12-01020]\]. Others predict the probability of interaction with other RNAs, such as mirDIP \[[@B187-cancers-12-01020]\] and LncRRISearch \[[@B188-cancers-12-01020]\]. There are also tools that can predict the regions where lncRNAs bind to genomic DNA, named LongTarget and LongMan \[[@B189-cancers-12-01020]\], the first being for a localized genomic region and the second for larger genomic areas. Finally, lncRNA secondary structure is important for these interactions, and it can be predicted by the RNAfold web server \[[@B190-cancers-12-01020]\], which calculates the minimum free energy conformation.

6. Conclusions and Perspectives {#sec6-cancers-12-01020}
===============================

LncRNAs are emerging tools important for diagnosis, prognosis and therapy. We have extensively reviewed the latest advances in lncRNA research in the context of ovarian cancer (OC). Although we can verify that there is a vast list of lncRNAs associated with OC, the problem arises when it comes to finding out which ones are the most useful to improve the management of the disease. As has been shown in this review and can be seen in the data provided in the [Supplementary Materials](#app1-cancers-12-01020){ref-type="app"}, some lncRNAs have been clearly identified as oncogenes, and alterations in their expression and their consequences in OC have been verified in independent cohorts, even by independent laboratories.

There are three main characteristics required to use these molecules as useful and valid biomarkers in OC diagnosis. The first one is that their variations in expression could be considered OC/cancer-specific. In practice, many of the reviewed lncRNAs have been tested by the receiver operating characteristic analysis to be able to successfully discern between OC and normal patients. The second is that they should occur in the early stages of the disease, although, only a few studies take into account samples from benign or borderline tumors which represent the earliest manifestation of the disease. The last required feature is that simple methods could be established for their quantification and detection, which allow their identification for massively testing the population at risk. However, there are pitfalls for implementing lncRNA screening in clinical practice because of technical issues and lack of ease of use and readiness. To detect lncRNAs, RNA-seq, RTqPCR, microarray hybridization and (F)ISH are the most common research techniques, but they are time-consuming. With the shifting perspectives in this field, new techniques are arising, such as loop-mediated isothermal amplification \[[@B191-cancers-12-01020]\] and isothermal reverse transcription-recombinase polymerase amplification \[[@B192-cancers-12-01020]\], which should make this task much easier and more feasible.

As we have seen throughout the review, some lncRNAs have also been related to sensitivity/resistance against drugs used in the treatment of OC or with more aggressive forms of the disease. Consequently, they could be used in prognosis and decision-making about the most suitable protocols in first and second-line therapies. Once the scientific community has identified and reached a consensus on which lncRNAs are the most useful in OC diagnosis and/or prognosis; their easy screening will be a scientific and technological advance that may be implemented through liquid biopsies from patient serum or different body fluids.

According to the evidence provided about the molecular mechanisms of some of these reviewed lncRNAs, they could be druggable targets for small interfering RNAs or antisense oligonucleotides, but this therapy is not yet possible in clinical practice owing to delivery problems, which could be solved by ongoing nanotechnological approaches. Additionally, in a recently opened research line, lncRNAs were regarded as true coding RNAs producing small peptides of less than 100 amino acids, which could be the real effectors of the lncRNAs in the cells and could have profound implications for cancer physiology \[[@B193-cancers-12-01020]\]. These lncRNAs and their derived peptides, which are also putative therapeutic targets to be tested in the next years, can be consulted in the database SmProt \[[@B175-cancers-12-01020]\].

Other upcoming approaches in this field could involve developing animal models for knockout or overexpression of lncRNAs, or patient-derived xenografts for personalized therapy. Promising data for better patient care awaits us as a result of ongoing and future research in this field.

The English text was edited by Biomedes (<http://www.biomedes.co.uk/>).

The following are available online at <https://www.mdpi.com/2072-6694/12/4/1020/s1>. Table S1: Overall experimental analyses of lncRNAs in OC (date 24/03/2020).
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cancers-12-01020-t001_Table 1

###### 

Long non-coding RNAs (lncRNAs) associated with clinicopathological variables in ovarian cancer (OC) patients.

  Tumor Size      Histological Dedifferentiation Grade                  Lymph Node Metastasis   Distant Metastasis                                                                                              
  --------------- ----------------------------------------------------- ----------------------- ---------------------------------------------------- --------------- ----------------------------- ------------ -----------------------------------------------------
  AB073614        \[[@B9-cancers-12-01020]\]                            ABHD11-AS1              \[[@B10-cancers-12-01020]\]                          AB073614        \[[@B9-cancers-12-01020]\]    DANCR        \[[@B11-cancers-12-01020]\]
  Casc15          \[[@B12-cancers-12-01020]\]                           aHIF                    \[[@B13-cancers-12-01020]\]                          AC093818.1      \[[@B14-cancers-12-01020]\]   FAM83H-AS1   \[[@B15-cancers-12-01020],[@B16-cancers-12-01020]\]
  Casc2           \[[@B17-cancers-12-01020]\]                           ANRIL                   \[[@B6-cancers-12-01020],[@B18-cancers-12-01020]\]   ADAMTS9-AS2     \[[@B19-cancers-12-01020]\]   FEZF1-AS1    \[[@B20-cancers-12-01020]\]
  DUXAP10         \[[@B6-cancers-12-01020]\]                            ASAP1-IT1               \[[@B21-cancers-12-01020]\]                          AK130076        \[[@B14-cancers-12-01020]\]   GAS5         \[[@B22-cancers-12-01020]\]
  EPB41L4A-AS2    \[[@B23-cancers-12-01020]\]                           Casc15                  \[[@B12-cancers-12-01020]\]                          ANRIL           \[[@B6-cancers-12-01020]\]    GHET1        \[[@B24-cancers-12-01020]\]
  FAM83H-AS1      \[[@B15-cancers-12-01020]\]                           Casc2                   \[[@B17-cancers-12-01020]\]                          Casc2           \[[@B17-cancers-12-01020]\]   JPX          \[[@B25-cancers-12-01020]\]
  GAS5            \[[@B22-cancers-12-01020],[@B26-cancers-12-01020]\]   CCAT1                   \[[@B6-cancers-12-01020]\]                           CCAT1           \[[@B6-cancers-12-01020]\]    LINC01210    \[[@B27-cancers-12-01020]\]
  GHET1           \[[@B24-cancers-12-01020]\]                           CCAT2                   \[[@B6-cancers-12-01020]\]                           CCAT2           \[[@B6-cancers-12-01020]\]    LncSOX4      \[[@B28-cancers-12-01020]\]
  HAGLROS         \[[@B29-cancers-12-01020]\]                           CPS1-IT1                \[[@B6-cancers-12-01020]\]                           CPS1-IT1        \[[@B6-cancers-12-01020]\]    LUCAT1       \[[@B30-cancers-12-01020]\]
  HOTAIR          \[[@B31-cancers-12-01020]\]                           DLEU1                   \[[@B32-cancers-12-01020]\]                          DLX6-AS1        \[[@B33-cancers-12-01020]\]   MAGI1-IT1    \[[@B34-cancers-12-01020]\]
  JPX             \[[@B25-cancers-12-01020]\]                           DUXAP10                 \[[@B6-cancers-12-01020]\]                           EIBC            \[[@B6-cancers-12-01020]\]    MALAT1       \[[@B6-cancers-12-01020]\]
  KCNQ1OT1        \[[@B35-cancers-12-01020]\]                           EIBC                    \[[@B6-cancers-12-01020]\]                           FAM83H-AS1      \[[@B15-cancers-12-01020]\]   MCM3AP-AS1   \[[@B36-cancers-12-01020]\]
  LINC00565       \[[@B37-cancers-12-01020]\]                           EPB41L4A-AS2            \[[@B23-cancers-12-01020]\]                          FAS-AS1         \[[@B14-cancers-12-01020]\]   MEG3         \[[@B38-cancers-12-01020]\]
  LINC00702       \[[@B39-cancers-12-01020]\]                           FAM215A                 \[[@B21-cancers-12-01020]\]                          FEZF1-AS1       \[[@B20-cancers-12-01020]\]   MLK7-AS1     \[[@B40-cancers-12-01020]\]
  LncSOX4         \[[@B28-cancers-12-01020]\]                           FAM83H-AS1              \[[@B16-cancers-12-01020]\]                          FLVCR1-AS1      \[[@B41-cancers-12-01020]\]   NEAT1        \[[@B42-cancers-12-01020]\]
  MORT            \[[@B43-cancers-12-01020]\]                           FEZF1-AS1               \[[@B20-cancers-12-01020]\]                          GAS5            \[[@B6-cancers-12-01020]\]    PCAT6        \[[@B44-cancers-12-01020]\]
  PCAT-1          \[[@B45-cancers-12-01020]\]                           GAS5                    \[[@B6-cancers-12-01020],[@B46-cancers-12-01020]\]   GTSE1-AS1       \[[@B14-cancers-12-01020]\]   SNHG12       \[[@B47-cancers-12-01020]\]
  RP11-135L22.1   \[[@B48-cancers-12-01020]\]                           HOTAIR                  \[[@B21-cancers-12-01020]\]                          HMMR-AS1        \[[@B49-cancers-12-01020]\]   SNHG20       \[[@B50-cancers-12-01020]\]
  TINCR           \[[@B51-cancers-12-01020]\]                           HOXA11-AS               \[[@B42-cancers-12-01020]\]                          HOTTIP          \[[@B52-cancers-12-01020]\]   TPT1-AS1     \[[@B53-cancers-12-01020]\]
  TPT1-AS1        \[[@B53-cancers-12-01020]\]                           KCNQ1OT1                \[[@B35-cancers-12-01020]\]                          HOXD-AS1        \[[@B6-cancers-12-01020]\]    XIST         \[[@B54-cancers-12-01020]\]
                                                                        LINC00339               \[[@B55-cancers-12-01020]\]                          LINC00515       \[[@B56-cancers-12-01020]\]                
                                                                        LINC00472               \[[@B42-cancers-12-01020]\]                          Linc-ROR        \[[@B57-cancers-12-01020]\]                
                                                                        LINC01088               \[[@B58-cancers-12-01020]\]                          lncARSR         \[[@B6-cancers-12-01020]\]                 
                                                                        Linc-ROR                \[[@B59-cancers-12-01020]\]                          lncBRM          \[[@B6-cancers-12-01020]\]                 
                                                                        lncARSR                 \[[@B6-cancers-12-01020]\]                           Lnc-OC1         \[[@B6-cancers-12-01020]\]                 
                                                                        lncBRM                  \[[@B6-cancers-12-01020]\]                           MCM3AP-AS1      \[[@B36-cancers-12-01020]\]                
                                                                        Lnc-OC1                 \[[@B6-cancers-12-01020]\]                           MIR22HG         \[[@B6-cancers-12-01020]\]                 
                                                                        MEG3                    \[[@B38-cancers-12-01020]\]                          MLK7-AS1        \[[@B40-cancers-12-01020]\]                
                                                                        MIR22HG                 \[[@B6-cancers-12-01020]\]                           MNX1-AS1        \[[@B6-cancers-12-01020]\]                 
                                                                        MNX1-AS1                \[[@B6-cancers-12-01020]\]                           NBAT-1          \[[@B6-cancers-12-01020]\]                 
                                                                        NBAT-1                  \[[@B6-cancers-12-01020]\]                           NEAT1           \[[@B6-cancers-12-01020]\]                 
                                                                        NEAT1                   \[[@B31-cancers-12-01020]\]                          NONHSAT076754   \[[@B60-cancers-12-01020]\]                
                                                                        NONHSAT076754           \[[@B60-cancers-12-01020]\]                          PCAT6           \[[@B44-cancers-12-01020]\]                
                                                                        SNHG20                  \[[@B61-cancers-12-01020]\]                          RP11-199F11.2   \[[@B14-cancers-12-01020]\]                
                                                                        SNHG5                   \[[@B62-cancers-12-01020]\]                          SNHG20          \[[@B61-cancers-12-01020]\]                
                                                                        SOX2OT                  \[[@B6-cancers-12-01020]\]                           SNHG3           \[[@B63-cancers-12-01020]\]                
                                                                        SPRY4-IT1               \[[@B6-cancers-12-01020]\]                           SNHG5           \[[@B62-cancers-12-01020]\]                
                                                                        TC0100223               \[[@B21-cancers-12-01020]\]                          SOCAR           \[[@B64-cancers-12-01020]\]                
                                                                        TC0101441               \[[@B21-cancers-12-01020]\]                          SOX2OT          \[[@B6-cancers-12-01020]\]                 
                                                                        TPT1-AS1                \[[@B53-cancers-12-01020]\]                          SPRY4-IT1       \[[@B6-cancers-12-01020]\]                 
                                                                        TUBA4B                  \[[@B6-cancers-12-01020]\]                           TC0100223       \[[@B42-cancers-12-01020]\]                
                                                                        XIST                    \[[@B54-cancers-12-01020]\]                          TC0101441       \[[@B42-cancers-12-01020]\]                
                                                                                                                                                     TINCR           \[[@B51-cancers-12-01020]\]                
                                                                                                                                                     TTN-AS1         \[[@B65-cancers-12-01020]\]                
                                                                                                                                                     TUBA4B          \[[@B6-cancers-12-01020]\]                 
                                                                                                                                                     UCA1            \[[@B21-cancers-12-01020]\]                

cancers-12-01020-t002_Table 2

###### 

LncRNAs associated with overall survival.

  Overall Survival                                                                                                                                                                                                                  
  ------------------ --------------------------------------------------- ------------ ----------------------------------------------------------------------------- --------------- ------------------------------ ---------------- -----------------------------------------------------------------------------
  AB073614           \[[@B6-cancers-12-01020],[@B9-cancers-12-01020]\]   FAM83H-AS1   \[[@B15-cancers-12-01020],[@B16-cancers-12-01020]\]                           LINC00504       \[[@B70-cancers-12-01020]\]    MLK7-AS1         \[[@B40-cancers-12-01020]\]
  AC104699.1.1       \[[@B42-cancers-12-01020]\]                         FEZF1-AS1    \[[@B20-cancers-12-01020],[@B71-cancers-12-01020]\]                           LINC00511       \[[@B72-cancers-12-01020]\]    MNX1-AS1         \[[@B6-cancers-12-01020]\]
  ADAMTS9-AS2        \[[@B19-cancers-12-01020]\]                         FLVCR1-AS1   \[[@B41-cancers-12-01020]\]                                                   LINC00565       \[[@B37-cancers-12-01020]\]    NEAT1            \[[@B6-cancers-12-01020]\]
  aHIF               \[[@B13-cancers-12-01020]\]                         GAS5         \[[@B22-cancers-12-01020],[@B31-cancers-12-01020],[@B46-cancers-12-01020]\]   LINC01125       \[[@B73-cancers-12-01020]\]    PVT1             \[[@B74-cancers-12-01020]\]
  AK021924           \[[@B42-cancers-12-01020]\]                         GIHCG        \[[@B75-cancers-12-01020]\]                                                   LINC01127       \[[@B76-cancers-12-01020]\]    RHPN1-AS1        \[[@B77-cancers-12-01020]\]
  AK094536           \[[@B42-cancers-12-01020]\]                         H19          \[[@B42-cancers-12-01020]\]                                                   LINC01210       \[[@B27-cancers-12-01020]\]    RP11-135L22.1    \[[@B48-cancers-12-01020]\]
  ANRIL              \[[@B6-cancers-12-01020]\]                          HAGLROS      \[[@B29-cancers-12-01020]\]                                                   LINC01627       \[[@B78-cancers-12-01020]\]    RP11-284N8.3.1   \[[@B21-cancers-12-01020]\]
  ASAP1-IT1          \[[@B42-cancers-12-01020]\]                         HAS2-AS1     \[[@B79-cancers-12-01020]\]                                                   LNC00908        \[[@B80-cancers-12-01020]\]    RP11-597D13.9    \[[@B81-cancers-12-01020]\]
  BC004123           \[[@B42-cancers-12-01020]\]                         HMMR-AS1     \[[@B49-cancers-12-01020]\]                                                   LNC01133        \[[@B82-cancers-12-01020]\]    RUNX1-IT1        \[[@B42-cancers-12-01020]\]
  BC007937           \[[@B42-cancers-12-01020]\]                         HOST2        \[[@B83-cancers-12-01020]\]                                                   lncARSR         \[[@B6-cancers-12-01020]\]     SNHG12           \[[@B47-cancers-12-01020]\]
  BC037530           \[[@B42-cancers-12-01020]\]                         HOTAIR       \[[@B21-cancers-12-01020]\]                                                   lncBRM          \[[@B6-cancers-12-01020]\]     SNHG14           \[[@B84-cancers-12-01020],[@B85-cancers-12-01020],[@B86-cancers-12-01020]\]
  BC062365           \[[@B42-cancers-12-01020]\]                         HOTAIRM1     \[[@B42-cancers-12-01020]\]                                                   lnc-HRCT1-1     \[[@B42-cancers-12-01020]\]    SNHG15           \[[@B67-cancers-12-01020]\]
  Casc15             \[[@B12-cancers-12-01020]\]                         HOTTIP       \[[@B52-cancers-12-01020],[@B87-cancers-12-01020]\]                           Lnc-OC1         \[[@B6-cancers-12-01020]\]     SNHG20           \[[@B61-cancers-12-01020]\]
  Casc2              \[[@B17-cancers-12-01020]\]                         HOXA11-AS    \[[@B6-cancers-12-01020]\]                                                    lnc-SERTAD2-3   \[[@B42-cancers-12-01020]\]    SNHG3            \[[@B63-cancers-12-01020],[@B88-cancers-12-01020]\]
  CCAT1              \[[@B6-cancers-12-01020]\]                          HOXD-AS1     \[[@B6-cancers-12-01020]\]                                                    LOC100190986    \[[@B42-cancers-12-01020]\]    SNHG5            \[[@B62-cancers-12-01020]\]
  CCAT2              \[[@B6-cancers-12-01020]\]                          JPX          \[[@B25-cancers-12-01020]\]                                                   LOXL1-AS1       \[[@B89-cancers-12-01020]\]    SPRY4-IT1        \[[@B42-cancers-12-01020]\]
  CCEPR              \[[@B90-cancers-12-01020]\]                         KCNMA1-AS1   \[[@B91-cancers-12-01020]\]                                                   LUCAT1          \[[@B30-cancers-12-01020]\]    TC0101441        \[[@B42-cancers-12-01020],[@B92-cancers-12-01020]\]
  DLX6-AS1           \[[@B33-cancers-12-01020]\]                         KCNQ1OT1     \[[@B35-cancers-12-01020],[@B93-cancers-12-01020]\]                           MALAT1          \[[@B94-cancers-12-01020]\]    TP73-AS1         \[[@B95-cancers-12-01020]\]
  DUXAP10            \[[@B42-cancers-12-01020]\]                         LEF1-AS1     \[[@B96-cancers-12-01020]\]                                                   MEG3            \[[@B38-cancers-12-01020]\]    TTN-AS1          \[[@B65-cancers-12-01020]\]
  EIBC               \[[@B6-cancers-12-01020]\]                          LINC00319    \[[@B97-cancers-12-01020]\]                                                   MIF-AS1         \[[@B98-cancers-12-01020]\]    UCA1             \[[@B26-cancers-12-01020]\]
  EPB41L4A-AS2       \[[@B23-cancers-12-01020]\]                         LINC00339    \[[@B55-cancers-12-01020]\]                                                   MIR22HG         \[[@B6-cancers-12-01020]\]     XIST             \[[@B54-cancers-12-01020],[@B99-cancers-12-01020]\]
  FAM215A            \[[@B42-cancers-12-01020]\]                         LINC00472    \[[@B21-cancers-12-01020]\]                                                   miR503HG        \[[@B100-cancers-12-01020]\]   ZFAS1            \[[@B101-cancers-12-01020]\]

cancers-12-01020-t003_Table 3

###### 

LncRNAs associated with patients' disease-free and progression-free survival.

  Disease-Free Survival   Progression-Free Survival                                                                                      
  ----------------------- ---------------------------------------------------- ----------- ----------------------------- --------------- -----------------------------------------------------
  DLX6-AS1                \[[@B33-cancers-12-01020]\]                          ANRIL       \[[@B6-cancers-12-01020]\]    lnc-HRCT1-1     \[[@B42-cancers-12-01020]\]
  GAS5                    \[[@B6-cancers-12-01020],[@B46-cancers-12-01020]\]   Casc15      \[[@B12-cancers-12-01020]\]   Lnc-OC1         \[[@B6-cancers-12-01020]\]
  H19                     \[[@B42-cancers-12-01020]\]                          Casc2       \[[@B17-cancers-12-01020]\]   lnc-SERTAD2-3   \[[@B42-cancers-12-01020]\]
  HOTAIR                  \[[@B21-cancers-12-01020]\]                          CCAT1       \[[@B6-cancers-12-01020]\]    MALAT1          \[[@B94-cancers-12-01020]\]
  HOTAIRM1                \[[@B42-cancers-12-01020]\]                          CCAT2       \[[@B6-cancers-12-01020]\]    MIR22HG         \[[@B6-cancers-12-01020]\]
  LINC01210               \[[@B27-cancers-12-01020]\]                          EIBC        \[[@B6-cancers-12-01020]\]    MNX1-AS1        \[[@B6-cancers-12-01020]\]
  LOC100190986            \[[@B42-cancers-12-01020]\]                          FLJ33360    \[[@B66-cancers-12-01020]\]   NEAT1           \[[@B6-cancers-12-01020]\]
  MALAT1                  \[[@B21-cancers-12-01020]\]                          HOXA11-AS   \[[@B6-cancers-12-01020]\]    SNHG15          \[[@B67-cancers-12-01020]\]
  RUNX1-IT1               \[[@B42-cancers-12-01020]\]                          HOXD-AS1    \[[@B6-cancers-12-01020]\]    SPRY4-IT1       \[[@B6-cancers-12-01020]\]
  TC0101441               \[[@B92-cancers-12-01020]\]                          lncARSR     \[[@B6-cancers-12-01020]\]    UCA1            \[[@B26-cancers-12-01020]\]
  ZFAS1                   \[[@B101-cancers-12-01020]\]                         lncBRM      \[[@B6-cancers-12-01020]\]    XIST            \[[@B42-cancers-12-01020],[@B54-cancers-12-01020]\]

cancers-12-01020-t004_Table 4

###### 

LncRNAs associated with resistance to most common chemotherapeutic drugs.

  Platinum Salts    Taxanes                                                                                                                                                                                         
  ----------------- ------------------------------------------------------- ----------------- ------------------------------ ---------------- ------------------------------------------------------- ------------- ------------------------------
  ANRIL             \[[@B18-cancers-12-01020]\]                             BC200             \[[@B21-cancers-12-01020]\]    CTD-2589M5.4\*   \[[@B102-cancers-12-01020]\]                            KB-1471A8.2   \[[@B103-cancers-12-01020]\]
  CCAT1             \[[@B104-cancers-12-01020]\]                            GAS5              \[[@B46-cancers-12-01020]\]    FER1L4           \[[@B105-cancers-12-01020]\]                            SNHG5         \[[@B62-cancers-12-01020]\]
  CCAT2             \[[@B106-cancers-12-01020]\]                            Linc00312         \[[@B6-cancers-12-01020]\]     NEAT1            \[[@B105-cancers-12-01020]\]                            XIST          \[[@B26-cancers-12-01020]\]
  CTD-2589M5.4\*    \[[@B102-cancers-12-01020]\]                            LINC00515         \[[@B21-cancers-12-01020]\]    PVT1             \[[@B105-cancers-12-01020]\]                                          
  DNM3OS            \[[@B107-cancers-12-01020]\]                            LINC01125         \[[@B73-cancers-12-01020]\]    UCA1             \[[@B105-cancers-12-01020],[@B108-cancers-12-01020]\]                 
  ENST00000457645   \[[@B6-cancers-12-01020]\]                              linc-TNFRSF19-1   \[[@B21-cancers-12-01020]\]                                                                                           
  FER1L4            \[[@B105-cancers-12-01020]\]                            MEG3              \[[@B42-cancers-12-01020]\]                                                                                           
  H19               \[[@B6-cancers-12-01020],[@B109-cancers-12-01020]\]     RP11-135L22.1     \[[@B48-cancers-12-01020]\]                                                                                           
  HOTAIR            \[[@B105-cancers-12-01020],[@B110-cancers-12-01020]\]   XIST              \[[@B111-cancers-12-01020]\]                                                                                          
  LINC00152         \[[@B112-cancers-12-01020]\]                                                                                                                                                                    
  Linc00161         \[[@B113-cancers-12-01020]\]                                                                                                                                                                    
  LINC00961         \[[@B21-cancers-12-01020]\]                                                                                                                                                                     
  linc-CARS2-2      \[[@B21-cancers-12-01020]\]                                                                                                                                                                     
  linc-RECK-3       \[[@B21-cancers-12-01020]\]                                                                                                                                                                     
  LUCAT1            \[[@B21-cancers-12-01020]\]                                                                                                                                                                     
  MALAT1            \[[@B107-cancers-12-01020]\]                                                                                                                                                                    
  NCK1-AS1          \[[@B114-cancers-12-01020]\]                                                                                                                                                                    
  NEAT1             \[[@B105-cancers-12-01020]\]                                                                                                                                                                    
  PVT1              \[[@B107-cancers-12-01020]\]                                                                                                                                                                    
  SNHG15            \[[@B67-cancers-12-01020]\]                                                                                                                                                                     
  UCA1              \[[@B105-cancers-12-01020]\]                                                                                                                                                                    
  ZFAS1             \[[@B6-cancers-12-01020]\]                                                                                                                                                                      

\* Co-expressed with genes associated with multidrug resistance. +, positively associated; −, negatively associated.
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###### 

LncRNA--miRNA--mRNA regulatory triplets.

  -------------------------------------------------------------------------------------------------------------------------------------
  lncRNA            miRNA                        mRNA                                                    Ref.
  ----------------- ---------------------------- ------------------------------------------------------- ------------------------------
  ADAMTS9-AS2       miR-182-5p                   FOXF2                                                   \[[@B19-cancers-12-01020]\]

  ANRIL             let-7a                       HMGA2                                                   \[[@B18-cancers-12-01020]\]

  BLACAT1           miR-519d-3p                  RPS15A                                                  \[[@B142-cancers-12-01020]\]

  Casc15            miR-221                      ARID1A                                                  \[[@B12-cancers-12-01020]\]

  CCAT1             miR-454                      Survivin                                                \[[@B104-cancers-12-01020]\]

  miR-1290          \-                           \[[@B6-cancers-12-01020]\]                              

  miR-130b          STAT3, ZEB1                                                                          

  miR-152           ADAM17, WNT1                                                                         

  CCAT2             miR-424                      \-                                                      \[[@B6-cancers-12-01020]\]

  DANCR             miR-145                      VEGF                                                    \[[@B133-cancers-12-01020]\]

  DARS-AS1          miR-532-3p                   \-                                                      \[[@B143-cancers-12-01020]\]

  DLEU1             miR-490-3p                   \-                                                      \[[@B32-cancers-12-01020]\]

  DLX6-AS1          miR-613                      \-                                                      \[[@B144-cancers-12-01020]\]

  EPB41L4A-AS2      miR-103a                     RUNX1T1                                                 \[[@B23-cancers-12-01020]\]

  EWSAT1            miR-330-5p                   Pdia3                                                   \[[@B6-cancers-12-01020]\]

  FEZF1-AS1         miR-130a-5p                  SOX4                                                    \[[@B20-cancers-12-01020]\]

  FLJ33360          miR-30b-3p                   \-                                                      \[[@B66-cancers-12-01020]\]

  FLVCRA1-AS1       miR-513                      YAP1                                                    \[[@B41-cancers-12-01020]\]

  GAS5              miR-196a-5p                  HOXA5                                                   \[[@B22-cancers-12-01020]\]

  miR-21            SPRY2                        \[[@B6-cancers-12-01020]\]                              

  H19               let-7                        HMGA2, c-MYC, IGF2BP                                    \[[@B31-cancers-12-01020]\]

  miR-324-5p        PKM2                         \[[@B132-cancers-12-01020]\]                            

  miR-370-3p        TGF-B                        \[[@B26-cancers-12-01020]\]                             

  HAS2-AS1          miR-466                      RUNX2                                                   \[[@B79-cancers-12-01020]\]

  HNF1A-AS1         miR-214                      SEMA4D, PlexinB1, Tiam1, Rac/1/2/3                      \[[@B134-cancers-12-01020]\]

  HOST2             let-7b                       HMGA2, c-Myc, Dicer, Imp3                               \[[@B31-cancers-12-01020]\]

  HOTAIR            miR-1                        MAPK1                                                   \[[@B145-cancers-12-01020]\]

  miR-200c          \-                           \[[@B146-cancers-12-01020]\]                            

  mir-214(-3p)      MAPK1, (PIK3R3)              \[[@B145-cancers-12-01020],[@B147-cancers-12-01020]\]   

  miR-217           PIK3R3                       \[[@B147-cancers-12-01020]\]                            

  miR-330-5p        MAPK1                        \[[@B145-cancers-12-01020]\]                            

  miR-373           Rab22a                       \[[@B6-cancers-12-01020]\]                              

  HOXD-AS1          miR-133a-3p                  \-                                                      \[[@B6-cancers-12-01020]\]

  miR-186-5p        PI3KR3                       \[[@B26-cancers-12-01020]\]                             

  HOXD-AS1          miR-608                      FZD4                                                    \[[@B26-cancers-12-01020]\]

  KCNQ1OT1          miR-142-5p                   CAPN10                                                  \[[@B93-cancers-12-01020]\]

  miR-212-3p        LCN2                         \[[@B35-cancers-12-01020]\]                             

  LINC00152         miR-125b                     MCL-1                                                   \[[@B6-cancers-12-01020]\]

  Linc00161         miR-194                      MAPK1                                                   \[[@B113-cancers-12-01020]\]

  LINC00319         miR-423-5p                   NACC1                                                   \[[@B97-cancers-12-01020]\]

  LINC00339         miR-148a-3p                  ROCK1                                                   \[[@B55-cancers-12-01020]\]

  LINC00504         miR-1244                     \-                                                      \[[@B70-cancers-12-01020]\]

  LINC01088         miR-24-1-5p                  PAK4                                                    \[[@B58-cancers-12-01020]\]

  LINC01125         miR-1972                     \-                                                      \[[@B73-cancers-12-01020]\]

  Linc-ROR          miR-145                      FLNB                                                    \[[@B59-cancers-12-01020]\]

  LNC00908          miR-495-5p                   ANXA3                                                   \[[@B80-cancers-12-01020]\]

  LNC01133          miR-126                      \-                                                      \[[@B82-cancers-12-01020]\]

  lncARSR           miR-200c                     ZEB1, ZEB2                                              \[[@B6-cancers-12-01020]\]

  lncBRM            miR-204                      \-                                                      \[[@B6-cancers-12-01020]\]

  Lnc-OC1           miR-34a                      \-                                                      \[[@B6-cancers-12-01020]\]

  miR-34c           \-                           \[[@B6-cancers-12-01020]\]                              

  LOXL1-AS1         miR-18b-5p                   VMA21                                                   \[[@B89-cancers-12-01020]\]

  LUCAT1            miR-612                      HOXA13                                                  \[[@B30-cancers-12-01020]\]

  miR-199a-5p       \-                           \[[@B148-cancers-12-01020]\]                            

  MAGI1-IT1         miR-200a                     ZEB1, ZEB2                                              \[[@B34-cancers-12-01020]\]

  MAGI2-AS3         miR-15b\                     HOXA5, MTSS1, PTEN, RECK                                \[[@B149-cancers-12-01020]\]
                    miR-374a\                                                                            
                    miR-374b                                                                             

  MALAT1            miR-143-3p                   CMPK                                                    \[[@B94-cancers-12-01020]\]

  miR-200c          \-                           \[[@B6-cancers-12-01020]\]                              

  miR-211           PHF19                        \[[@B6-cancers-12-01020]\]                              

  miR-503-5p        pJak2, pSTAT3                \[[@B150-cancers-12-01020]\]                            

  miR-506           iASPP                        \[[@B6-cancers-12-01020]\]                              

  MCM3AP-AS1        miR-28-5p                    \-                                                      \[[@B36-cancers-12-01020]\]

  MIAT              miR-150-5p                   \-                                                      \[[@B151-cancers-12-01020]\]

  MIF-AS1           miR-315p                     PLCB1                                                   \[[@B98-cancers-12-01020]\]

  MEG3              miR-214                      \-                                                      \[[@B107-cancers-12-01020]\]

  miR-219a-5p       EGFR                         \[[@B38-cancers-12-01020]\]                             

  miR-421           PDGFRA, NOTCH1, HES1, RBPJ   \[[@B123-cancers-12-01020]\]                            

  MLK7-AS1          miR-375                      YAP1                                                    \[[@B40-cancers-12-01020]\]

  NCK1-AS1          miR-137                      NCK1                                                    \[[@B114-cancers-12-01020]\]

  NEAT1             miR-124                      \-                                                      \[[@B21-cancers-12-01020]\]

  miR-194           ZEB1                         \[[@B105-cancers-12-01020]\]                            

  miR-382-3p        ROCK1                        \[[@B6-cancers-12-01020]\]                              

  miR-506           RAD51                        \[[@B105-cancers-12-01020]\]                            

  NORAD             miR-155-5p                   \-                                                      \[[@B115-cancers-12-01020]\]

  miR-199a-3p       \-                           \[[@B152-cancers-12-01020]\]                            

  miR-608           STAT3                        \[[@B116-cancers-12-01020]\]                            

  PCA3              miR-106b                     RhoC, Bcl/xL, P70S6K, MMP2                              \[[@B6-cancers-12-01020]\]

  PTAF              miR-25                       SNAI2                                                   \[[@B6-cancers-12-01020]\]

  PTAL/AC004988.1   miR-101                      FN1                                                     \[[@B153-cancers-12-01020]\]

  PTAR              miR-101-3p                   ZEB1                                                    \[[@B154-cancers-12-01020]\]

  PVT1              miR-133a                     \-                                                      \[[@B6-cancers-12-01020]\]

  miR-140                                        \[[@B74-cancers-12-01020]\]                             

  RHPN1-AS1         miR-596-3p                   LETM1                                                   \[[@B77-cancers-12-01020]\]

  SNHG12            miR-129                      SOX4                                                    \[[@B47-cancers-12-01020]\]

  SNHG14            miR-125a-5p                  DHX33                                                   \[[@B86-cancers-12-01020]\]

  miR-219a-5p       \-                           \[[@B84-cancers-12-01020]\]                             

  SNHG3             miR-186a-5p\                 \-                                                      \[[@B88-cancers-12-01020]\]
                    miR-590-3p                                                                           

  SNHG5             miR-23a                      \-                                                      \[[@B62-cancers-12-01020]\]

  TDRG1             miR-93                       RhoC, P70S6K, Bcl-xL, MMP2                              \[[@B6-cancers-12-01020]\]

  TINCR             miR-335                      FGF2                                                    \[[@B51-cancers-12-01020]\]

  TTN-AS1           miR-139-5p                   ROCK2                                                   \[[@B65-cancers-12-01020]\]

  miR-15b-5p        FBXW7                        \[[@B124-cancers-12-01020]\]                            

  TUG1              miR-29b-3p                   MDM2                                                    \[[@B155-cancers-12-01020]\]

  UCA1              miR-129                      ABCB1                                                   \[[@B105-cancers-12-01020]\]

  miR-485-5p        MMP14                        \[[@B21-cancers-12-01020]\]                             

  miR-654-5p        SIK2                         \[[@B108-cancers-12-01020]\]                            

  WDFY3-AS2         miR-18a                      RORA                                                    \[[@B156-cancers-12-01020]\]

  XIST              miR-150-5p                   PDCD4                                                   \[[@B99-cancers-12-01020]\]

  miR-214-3p        PTEN                         \[[@B105-cancers-12-01020]\]                            

  ZFAS1             miR-150-5p                   Sp1                                                     \[[@B6-cancers-12-01020]\]
  -------------------------------------------------------------------------------------------------------------------------------------
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###### 

Online databases containing useful information for the study of lncRNAs in ovarian cancer.

  Name              Description                                                              Link                                                          Ref.
  ----------------- ------------------------------------------------------------------------ ------------------------------------------------------------- ------------------------------
  GEPIA 2           Gene Expression Profiling Interactive Analysis                           <http://gepia2.cancer-pku.cn/#index>                          \[[@B159-cancers-12-01020]\]
  CCLE              Cancer Cell Line Encyclopedia                                            <https://portals.broadinstitute.org/ccle>                     \[[@B160-cancers-12-01020]\]
  TANRIC            The Atlas of non-coding RNA in Cancer                                    <https://ibl.mdanderson.org/tanric/_design/basic/main.html>   \[[@B161-cancers-12-01020]\]
  LNCipedia         Database for lncRNA                                                      <https://lncipedia.org/>                                      \[[@B162-cancers-12-01020]\]
  NONCODE           Database dedicated to ncRNA, especially lncRNA                           <http://www.noncode.org/>                                     \[[@B163-cancers-12-01020]\]
  AnnoLnc           Database                                                                 <http://annolnc.cbi.pku.edu.cn/index.jsp>                     \[[@B164-cancers-12-01020]\]
  lncRNAdb          Database                                                                 <http://lncrnadb.org/>                                        \[[@B165-cancers-12-01020]\]
  lncRBase          Database                                                                 <http://bicresources.jcbose.ac.in/zhumur/lncrbase/>           \[[@B166-cancers-12-01020]\]
  RNAInter          RNA interactome database                                                 <http://www.rna-society.org/rnainter>                         \[[@B167-cancers-12-01020]\]
  StarBase-ENCORI   The Encyclopedia of RNA Interactomes                                     <http://starbase.sysu.edu.cn>                                 \[[@B168-cancers-12-01020]\]
  miRTarBase        microRNA-target interactions database                                    <http://mirtarbase.mbc.nctu.edu.tw/php/index.php>             \[[@B169-cancers-12-01020]\]
  ORTI              Open-access Repository of Transcriptional Interaction                    <http://orti.sydney.edu.au/index.html>                        \[[@B170-cancers-12-01020]\]
  DiseaseMeth       Human disease methylation database                                       <http://bio-bigdata.hrbmu.edu.cn/diseasemeth/>                \[[@B171-cancers-12-01020]\]
  Lnc2Meth          Relationships between lncRNAs and DNA methylation                        <http://bio-bigdata.hrbmu.edu.cn/Lnc2Meth/index.jsp>          \[[@B172-cancers-12-01020]\]
  LncRNA2Target     Database of experiments focused on lncRNA in human and mouse             <http://123.59.132.21/lncrna2target/>                         \[[@B173-cancers-12-01020]\]
  CRISPRlnc         Validated CRISPR/Cas9 sgRNAs for lncRNAs from all species                <http://www.crisprlnc.org/>                                   \[[@B174-cancers-12-01020]\]
  SmProt            Small Proteins (\< 100 aa) especially encoded by non-coding RNAs         <http://bioinfo.ibp.ac.cn/SmProt/index.htm>                   \[[@B175-cancers-12-01020]\]
  LncTarD           Database for functional lncRNA-target regulation in human diseases       <http://biocc.hrbmu.edu.cn/LncTarD/>                          \[[@B176-cancers-12-01020]\]
  LncRNADisease     The LncRNA and Disease Database                                          <http://www.rnanut.net/lncrnadisease/>                        \[[@B177-cancers-12-01020]\]
  LncMAP            LncRNA Modulator Atlas in Pan-cancer                                     <http://bio-bigdata.hrbmu.edu.cn/LncMAP/>                     \[[@B178-cancers-12-01020]\]
  Lnc2Cancer        Experimentally supported associations between lncRNA and human cancer.   <http://www.bio-bigdata.com/lnc2cancer/>                      \[[@B179-cancers-12-01020]\]
  CRlncRNA          Cancer-related lncRNA Database                                           <http://crlnc.xtbg.ac.cn>                                     \[[@B180-cancers-12-01020]\]
  EMT-Regulome      Database for EMT-related regulatory interactions, motifs and network     <http://www.medsysbio.org/EMTRegulome>                        \[[@B181-cancers-12-01020]\]
  RHPCG             Regulation of the Hippo Pathway in Cancer Genome                         <http://www.medsysbio.org/RHPCG>                              \[[@B182-cancers-12-01020]\]
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###### 

Online tools useful for predicting lncRNA interactions and structures.

  Name                   Description                                                                                Link                                                            Ref.
  ---------------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------- ------------------------------
  RPISeq                 RNA-Protein Interaction Prediction                                                         <http://pridb.gdcb.iastate.edu/RPISeq/>                         \[[@B183-cancers-12-01020]\]
  RPI-Pred               RNA-protein interaction prediction server                                                  <http://ctsb.is.wfubmc.edu/projects/rpi-pred/>                  \[[@B184-cancers-12-01020]\]
  lncPro                 Prediction of lncRNA-protein interactions                                                  <http://bioinfo.bjmu.edu.cn/lncpro/>                            \[[@B185-cancers-12-01020]\]
  catRAPID               Algorithm to estimate the binding propensity of protein-RNA pairs                          <http://s.tartaglialab.com/page/catrapid_group>                 \[[@B186-cancers-12-01020]\]
  mirDIP                 microRNA Data Integration Portal                                                           <http://ophid.utoronto.ca/mirDIP/>                              \[[@B187-cancers-12-01020]\]
  LncRRISearch           lncRNA-RNA interaction prediction                                                          <http://rtools.cbrc.jp/LncRRIsearch/>                           \[[@B188-cancers-12-01020]\]
  LongTarget & LongMan   Predict a lncRNA's DNA binding motifs and binding sites, locally or at genome-wide scale   <http://lncrna.smu.edu.cn/>                                     \[[@B189-cancers-12-01020]\]
  RNAfold web server     Predicts RNA secondary structures                                                          <http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi>   \[[@B190-cancers-12-01020]\]
